Loading...
XKRX
200230
Market cap463mUSD
Jul 29, Last price  
5,750.00KRW
1D
3.60%
1Q
38.72%
Jan 2017
34.50%
IPO
-14.81%
Name

Telcon RF Pharmaceutical Inc

Chart & Performance

D1W1MN
P/E
—
P/S
16.99
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-31.97%
Rev. gr., 5y
-6.32%
Revenues
37.87b
+4.29%
35,223,848,24046,638,653,45058,756,395,20028,542,710,49529,840,249,47641,149,342,28657,708,456,06852,478,096,80333,141,153,91037,841,150,31527,829,999,16936,307,203,77037,865,282,080
Net income
-26.32b
L
4,478,716,7907,889,196,8106,741,459,320348,205,166-3,438,171,142-16,440,417,431-13,754,594,876-52,648,899,647-40,892,851,943-23,098,051,471-42,084,350,43813,906,405,519-26,319,870,060
CFO
1.22b
P
1,921,810,48012,616,833,7901,473,391,6802,267,158,491-3,969,489,818-9,868,413,228-9,249,386,6985,012,725,8542,802,856,787-358,558,813-2,092,882,466-1,134,685,9201,218,843,170
Earnings
Aug 12, 2025

Profile

TELCON RF PHARMACEUTICAL. Inc. develops, produces, and sells RF coaxial connectors worldwide. It also provides coaxial couplers, distributors, and arresters, as well as cable assemblies. The company was formerly known as Telcon Co., Ltd. TELCON RF PHARMACEUTICAL. Inc. was founded in 1999 and is based in Yongin-si, South Korea.
URL
https://www.telcon.co.kr/
IPO date
Nov 24, 2014
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
37,865,282
4.29%
36,307,204
30.46%
27,829,999
-26.46%
Cost of revenue
30,725,142
28,800,426
27,622,109
Unusual Expense (Income)
NOPBT
7,140,140
7,506,778
207,890
NOPBT Margin
18.86%
20.68%
0.75%
Operating Taxes
(1,979,114)
(32,809)
Tax Rate
NOPAT
7,140,140
9,485,892
240,699
Net income
(26,319,870)
-289.26%
13,906,406
-133.04%
(42,084,350)
82.20%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
55,100,901
27,020,267
29,547,364
Long-term debt
1,617,374
1,383,196
1,455,701
Deferred revenue
Other long-term liabilities
143,391
143,412
62,771
Net debt
(41,473,797)
(56,915,103)
(42,938,807)
Cash flow
Cash from operating activities
1,218,843
(1,134,686)
(2,092,882)
CAPEX
(4,967,815)
(1,897,846)
(833,955)
Cash from investing activities
(44,083,849)
(10,524,640)
(7,885,465)
Cash from financing activities
37,651,166
10,445,303
(3,440,268)
FCF
17,640,274
3,101,277
1,594,585
Balance
Cash
10,036,804
10,519,043
9,733,525
Long term investments
88,155,269
74,799,523
64,208,346
Excess cash
96,298,808
83,503,206
72,550,372
Stockholders' equity
(168,131,539)
(139,155,703)
(149,331,594)
Invested Capital
306,795,095
271,666,936
263,804,893
ROIC
2.47%
3.54%
0.09%
ROCE
5.14%
5.67%
0.18%
EV
Common stock shares outstanding
12,076
149,546
106,081
Price
5,870.00
572.39%
873.00
-13.99%
1,015.00
-65.30%
Market cap
70,887,523
-45.70%
130,553,376
21.25%
107,672,585
-58.10%
EV
29,719,076
74,123,736
64,746,035
EBITDA
11,646,857
11,751,015
4,489,354
EV/EBITDA
2.55
6.31
14.42
Interest
3,759,900
603,578
1,062,740
Interest/NOPBT
52.66%
8.04%
511.20%